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Background: The purpose of this nested case-control study in Denmark was to study the 
association between use of corticosteroids and risk of miscarriage.
Methods: We identified prescriptions for corticosteroids before the miscarriage/index 
date. We estimated odds ratios (ORs) for miscarriage and for early (,13 weeks) and late 
(13–21 weeks) miscarriage adjusting for age, history of diabetes and epilepsy, and nonsteroidal 
anti- inflammatory drug use.
Results: We identified 10,974 women with miscarriage and 109,740 controls. Prevalence of 
inhaled corticosteroid use within 60 days before the index date was 1.3% among the cases and 
1.0% among the controls (OR = 1.20; 95% confidence interval [CI] 1.01–1.44). Prevalence 
of oral corticosteroid use within 60 days before the index date was 0.3% for both cases and 
controls (OR = 0.78; 95% CI 0.53–1.15). For inhaled and oral corticosteroids, the ORs of early 
miscarriage were 1.22 (95% CI 1.01–1.49) and 0.81 (95% CI 0.55–1.20), respectively.
Conclusion: Use of inhaled corticosteroids was associated with a slightly increased risk of 
early miscarriage, but explanations alternative to causal ones were possible.
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Introduction
Corticosteroid hormones are potent substances that influence the functioning of 
most cells in the body,1 and are used in women of childbearing age2,3 to treat asthma, 
rheumatoid arthritis, eczema, and inflammatory bowel disease.4,5 In Denmark, an 
estimated 1.7% of women who give birth use inhaled or oral corticosteroids during 
early pregnancy.6
Miscarriage is the most common adverse event of early pregnancy, occurring in 
approximately 20% of pregnancies.7 Previously, four studies have examined corticos-
teroid use in pregnancies ending in miscarriage, with numbers of pregnancies ranging 
from 3138 to 281,019.9 All of the studies,8–10 except one,11 reported an increased risk 
of miscarriage among women with corticosteroid intake in early pregnancy, with risk 
ratios ranging from 1.01 (95% confidence interval [CI] 0.48–2.11)11 to 1.66 (95% 
CI 1.12–2.48).10 Most published studies were conducted on small samples and not 
population-based.8,10,11 Potential confounding by age, smoking, and body mass index 
could be controlled in only one study.9 Also, no study accounted for gestational age at 
the time of miscarriage, although this information could reveal potential mechanisms 
behind the putative association.
We conducted a large population-based nested case-control study to examine 
the relationship between use of corticosteroids and risk of miscarriage. Further, we 
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examined whether the association differed for early and late 
miscarriage.
Materials and methods
Study population and duration
The population of this case-control study stemmed from 
northern Denmark, which is a well-defined geographic and 
administrative region with a population of about 1.8 million 
people or 33% of the total Danish population. Approximately 
23,500 births are registered each year in the region.12 The study 
period extended from January 1, 1997 to December 31, 2009. 
Denmark’s tax-funded health care system ensures equal access 
to health services and partial reimbursement of most prescription 
drugs.13 The unique ten-digit personal identifier (CPR number) 
assigned to Danish residents at birth or upon immigration by 
the civil registration system14 encodes date of birth and gender, 
and is used in all public records, allowing for unambiguous 
record linkage across data from different registries.
Cases
Cases were women with a first-time miscarriage before the 
22nd gestational week and no record of previous delivery. 
Cases were identified in the Danish National Registry of 
Patients (DNRP), which tracks admissions to all Danish 
somatic hospitals since 1977, including diagnoses and 
procedures; from 1995 onwards, information on outpatient 
visits has been included.15 Diagnoses are coded by doctors at 
discharge, using the International Classification of Diseases, 
Eighth Revision (ICD-8) before 1994 and Tenth Revision 
(ICD-10) thereafter. Gestational age at miscarriage has 
been reported to the DNRP since 1997 and is registered at 
diagnosis. Gestational age in Denmark is estimated mainly 
on the basis of ultrasound examination.16 The index date for 
the cases was the date of an inpatient or outpatient hospital 
visit with a diagnosis of miscarriage. We further divided 
miscarriage into early miscarriage as occurring in the first 
trimester (up to 12 completed gestational weeks) and late 
miscarriage as occurring in the second trimester (from 
gestational week 13 until gestational week 22).
Controls
Controls were women without a history of miscarriage, 
delivering their first live newborn. To identify controls, we 
used the Danish Medical Birth Registry,17 which has tracked 
all births in Denmark since 1973. For each case, we sampled 
10 controls from women whose estimated date of concep-
tion (date of delivery minus recorded gestational length plus 
14 days) was in the same calendar year as that of the case. 
The index date for controls was the date on which the fetus 
had the same gestational age as the fetus of the calendar-year 
matched case woman at the date of miscarriage.
Use of corticosteroids
We used the Aarhus University Prescription Database to 
identify prescriptions for inhaled and oral corticosteroids 
filled by cases and controls before the index date. This 
database tracks prescriptions of reimbursed drugs sold at 
community pharmacies in northern Denmark.18 Inhaled and 
oral corticosteroids, which are available by prescription 
only, are eligible for general reimbursement in Denmark 
and thus generate records in the database. For all relevant 
prescriptions filled by the women in our study, we noted 
date of dispensation and type of drug, coded according to 
the Anatomical Therapeutic Chemical classification system. 
In some areas of the region, data on dispensations were 
available starting in 1998. We restricted our sample to women 
whose prescriptions, based on their place of residence, were 
expected to be recorded in the database for a minimum of 
one year before the index date.
Use was defined as a record of at least one relevant pre-
scription. We defined the following categories of inhaled or 
oral corticosteroid users according to the recency of their last 
prescription relative to the index date: current users, with 
the most recent prescription filled within 60 days before the 
index date; recent users, with the most recent prescription 
filled 61–180 days before the index date; former users, with 
the most recent prescription filled more than 180 days before 
the index date; and never users, with no record of dispensed 
inhaled or oral corticosteroids in the prescription database 
before the index date (the reference group). Within the cat-
egory of current users, we singled out new users, whose first 
recorded prescription of inhaled or oral corticosteroids was 
dispensed within 60 days before the index date.
Potential confounders
From the DNRP, we obtained information about maternal 
diagnoses of diseases typically treated with corticosteroids, 
ie, asthma, rheumatoid arthritis, and inflammatory bowel 
disease, recorded from 1977 until delivery. We identified 
history of diabetes or epilepsy before the index date 
using discharge diagnoses from hospital admissions or 
outpatient/emergency visits or by prescriptions redeemed for 
antidiabetic or antiepileptic drugs. Both diseases have been 
associated with an increased risk of miscarriage.19,20 For the 
same reason, we obtained data on women’s prescriptions for 
nonsteroidal anti-inflammatory drugs (NSAIDs) redeemed 
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within 12 weeks before the index date.21 All relevant diagnostic 
and drug codes are listed in Supplementary Table 1.
Statistical analysis
We summarized the demographic characteristics and medical 
history of cases and controls. We used conditional logistic 
regression to estimate odds ratios (ORs) with 95% confiden-
tial intervals (CIs) for the association between corticosteroid 
use and risk of miscarriage, separately for oral and inhaled 
preparations, and adjusting for age, past medical history of 
diabetes and epilepsy, and NSAID use. We then examined 
the association of corticosteroid use separately for early and 
late miscarriages.
Finally, we conducted a series of sensitivity analyses. We 
examined whether variation in the definition of corticoster-
oid exposure affected the results by extending the definition 
of current and new use from 60 days to 90 days before the 
index date. We then recalculated ORs after excluding cases 
and controls with a history of induced abortion in order to 
examine the impact of previous pregnancy loss. We used 
SAS® version 9.2 software for all analyses (SAS Institute, 
Cary, NC, USA). This study was approved by the Danish 
Data Protection Agency (2003-41-3103).
Results
Characteristics of participants
We identified 10,974 women with first-time miscarriage and 
109,740 matched controls with first-time live births. Cases 
were more likely than controls to be 30 years or older on the 
index date (34.1% versus 26.9%). Cases and controls were 
similar with respect to medical history before the index date 
(Table 1).
Corticosteroid use
The distribution of current, recent, and former corticosteroid use 
was similar between cases and controls (Table 1). For inhaled 
corticosteroids, the adjusted OR for miscarriage was 1.20 (95% 
CI 1.01–1.44) for current use and 1.05 (95% CI 0.96–1.15) for 
former use (Table 2). For oral corticosteroid use, the adjusted 
OR for miscarriage was 0.78 (95% CI 0.53–1.15) for current 
use and 1.07 (95% CI 0.97–1.18) for former use.
Early versus late miscarriage
Early miscarriages accounted for 9,735/10,974 of all recorded 
miscarriages (88.7%). Among women with early miscarriage, 
129 (1.3%) were current users of inhaled corticosteroids while 
11 (0.9%) women with late miscarriage were current users of 
these medications. Table 3 shows the ORs for early and late 
miscarriage according to inhaled and oral corticosteroids. 
For current users of inhaled corticosteroids, the adjusted ORs 
for early and late miscarriage were 1.22 (95% CI 1.01–1.49) 
and 1.06 (95% CI 0.56–1.99), respectively. Only 27 (0.3%) 
women with early miscarriage and one woman with late 
miscarriage were current users of oral corticosteroids.
Sensitivity analyses
When the definition of current use was extended to 90 days 
before the index date, prevalence of current use of inhaled 
corticosteroids was 1.5% among the cases and 1.3% 
among the controls (adjusted OR 1.09; 95% CI 0.92–1.28). 
According to the extended definition, prevalence of current 
use of oral corticosteroids was 0.3% among the cases 
Table 1 Characteristics of women with a first-time miscarriage 
(cases) and women with a first live birth (controls), northern 
Denmark, 1997–2009
Cases 
n (%)
Controls 
n (%)
Total number 10,974 109,740
Corticosteroid use
Corticosteroids, overall
 Current 165 (1.5) 1,447 (1.3)
 Recent 118 (1.1) 1,286 (1.2)
 Former 976 (8.9) 9,213 (8.4)
 Never 9,768 (89.0) 98,291 (89.6)
 New 19 (0.2) 245 (0.2)
inhaled corticosteroids*
 Current 140 (1.3) 1,143 (1.0)
 Recent 87 (0.8) 907 (0.8)
 Former 575 (5.2) 5,496 (5.0)
 Never 10,172 (92.7) 102,194 (93.1)
 New 9 (0.1) 95 (0.1)
Oral corticosteroids¤
 Current 28 (0.3) 341 (0.3)
 Recent 35 (0.3) 411 (0.4)
 Former 474 (4.3) 4,387 (4.0)
 Never 10,437 (95.1) 104,601 (95.3)
 New 10 (0.1) 171 (0.2)
Potential confounders
Age at index date
 ,25 years 2,931 (26.7) 28,523 (26.0)
 25–29 years 4,302 (39.2) 51,694 (47.1)
 $30 years 3,741 (34.1) 29,523 (26.9)
Past medical history
 Asthma 343 (3.1) 2,982 (2.7)
 Rheumatoid arthritis 30 (0.3) 171 (0.2)
 Inflammatory bowel disease 76 (0.7) 838 (0.8)
 Diabetes 175 (1.6) 1,715 (1.6)
 Epilepsy 233 (2.1) 2,034 (1.9)
 Use of NSAiDs 441 (4.0) 3,469 (3.2)
Note: *Inhaled corticosteroids are mainly used to treat asthma; ¤oral corticosteroids 
are mainly used to treat inflammatory bowel disease and rheumatoid arthritis. 
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.
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and 0.4% among the controls (adjusted OR 0.74; 95% 
CI 0.52–1.05). Excluding 1,585 cases (14.4%) and 13,197 
controls (12.0%) with a record of induced abortion did not 
change the interpretation of the overall results (data avail-
able on request).
Discussion
In this large population-based, case-control study, current 
use of inhaled corticosteroids was associated with a slightly 
increased risk of miscarriage during the first 12 weeks of 
gestation as compared with no recorded use. There was no 
evidence of an association between use of oral corticosteroids 
and risk of miscarriage.
Our study extends earlier research by including informa-
tion on gestational age at miscarriage. Because the etiology of 
miscarriage varies according to gestational age,22 an associa-
tion between corticosteroid exposure and early but not late 
miscarriage is an important finding. An early miscarriage may 
represent fetal loss secondary to malformation incompatible 
with fetal survival. Studies of maternal use of inhaled and 
oral corticosteroids in early gestation and risk of congenital 
malformations in offspring have been inconclusive.4,6,10,11,23–30 
Selection bias arising from early-gestation miscarriage of 
malformed embryos could explain the lack of an apparent 
association, if such an association exists.31,32
Presence of an association with miscarriage for inhaled 
but not oral corticosteroids is counterintuitive. Oral cor-
ticosteroids reach higher concentrations in the maternal 
circulation1 and therefore could be expected to lead to 
higher levels of fetal exposure. An abnormal maternal 
immune response has been assumed to act as an initiator of 
miscarriage.22,33 The anti-inflammatory effect of corticoster-
oids might protect against this if given in high doses. In fact, 
high doses of corticosteroids are used to prevent recurrent 
miscarriages,34 although the effectiveness of this treatment 
is still controversial.34–36
The association observed for inhaled corticosteroids 
may be due to confounding by asthma,37 because asthma 
is a common indication for inhaled corticosteroids. 
Asthma exacerbations induce hypoxia and may induce 
Table 3 Use of oral and inhaled corticosteroid prescriptions stratified by early miscarriage (gestational weeks 1–12) or late miscarriage 
(gestational weeks 13–21), northern Denmark, 1997–2009
Corticosteroid  
use
Early miscarriage Late miscarriage
Case/control 
ratio
Unadjusted OR 
(95% CI)
Adjusted OR*  
(95% CI)
Case/control 
ratio
Unadjusted OR 
(95% CI)
Adjusted OR* 
(95% CI)
inhaled corticosteroids
 Current 129/1,047 1.24 (1.03–1.49) 1.22 (1.01–1.49) 11/96 1.09 (0.58–2.04) 1.06 (0.56–1.99)
 Recent 74/786 0.93 (0.73–1.18) 0.92 (0.72–1.17) 13/121 1.07 (0.60–1.91) 1.06 (0.59–1.89)
 Former 515/4,867 1.06 (0.97–1.17) 1.07 (0.97–1.17) 60/629 0.95 (0.72–1.25) 0.97 (0.74–1.27)
 Never 9,017/90,650 Reference Reference 1,155/11,544 Reference Reference
 New 9/88 0.99 (0.50–1.97) 0.93 (0.47–1.86) 0/7 – –
Oral corticosteroids
 Current 27/318 0.86 (0.58–1.27) 0.81 (0.55–1.20) 1/23 0.41 (0.06–3.06) –
 Recent 32/367 0.87 (0.61–1.25) 0.87 (0.60–1.25) 3/44 0.70 (0.22–2.26) 0.68 (0.21–2.20)
 Former 431/3,884 1.11 (1.01–1.23) 1.10 (0.99–1.22) 43/503 0.85 (0.62–1.17) 0.83 (0.61–1.14)
 Never 9,245/92,781 Reference Reference 1,192/11,820 Reference Reference
 New 10/164 0.63 (0.33–1.19) 0.59 (0.31–1.12) 0/7 – –
Note: *Adjusted for age at index date, history of diabetes and epilepsy, and use of NSAiDS in the 12 weeks before the index date. 
Abbreviations: OR, odds ratio; CI, confidence interval; NSAIDs, nonsteroidal anti-inflammatory drugs.
Table 2 Use of inhaled and oral corticosteroids and miscarriage 
among women in northern Denmark, 1997–2009
Corticosteroid 
use
Case/control 
ratio
Unadjusted  
OR (95% CI)
Adjusted  
OR* (95% CI)
Corticosteroids overall
 Current 165/1,447 1.15 (0.97–1.35) 1.11 (0.95–1.31)
 Recent 118/1,286 0.92 (0.76–1.12) 0.92 (0.76–1.11)
 Former 976/9,213 1.07 (1.00–1.14) 1.07 (0.99–1.14)
 Never 9,768/98,291 Reference Reference
 New 19/245 0.78 (0.49–1.25) 0.75 (0.47–1.19)
inhaled corticosteroids
 Current 140/1,143 1.23 (1.03–1.47) 1.20 (1.01–1.44)
 Recent 87/907 0.95 (0.76–1.19) 0.94 (0.75–1.17)
 Former 575/5,496 1.05 (0.96–1.15) 1.05 (0.96–1.15)
 Never 10,172/102,194 Reference Reference
 New 9/95 0.92 (0.46–1.82) 0.86 (0.43–1.72)
Oral corticosteroids
 Current 28/341 0.82 (0.56–1.21) 0.78 (0.53–1.15)
 Recent 35/411 0.85 (0.60–1.21) 0.85 (0.60–1.20)
 Former 474/4,387 1.08 (0.98–1.19) 1.07 (0.97–1.18)
 Never 10,437/104,601 Reference Reference
 New 10/171 0.60 (0.32–1.14) 0.57 (0.30–1.07)
Note: *Adjusted for age at index date, history of diabetes and epilepsy, and use of 
NSAiDS 12 weeks before the index date.
Abbreviations: OR, odds ratio; CI, confidence interval; NSAIDs, nonsteroidal anti-
inflammatory drugs.
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abnormal smooth muscle activity in the uterus, similar to 
airway smooth muscle contractions, and therefore could 
be a risk factor for miscarriage.30,38,39 Although prevalence of 
asthma diagnoses between cases and controls did not differ 
substantially in our study, there could be residual confounding 
by asthma not leading to hospital contact37 and therefore not 
measured in our study.
Our study corroborates a large prevalence study based on 
The Health Improvement Network in the United Kingdom 
of almost 300,000 pregnancies. It was conducted to quantify 
risks of major adverse pregnancy outcomes and obstetric 
complications in women with and without asthma. The study 
reported a higher risk of miscarriage (adjusted OR 1.24; 95% 
CI 1.17–1.34) among women who used inhaled corticoster-
oids compared with women who did not, after controlling for 
age, smoking, and body mass index.9 Similarly, a cohort study 
based on data from an international asthma trial reported 
an unadjusted relative risk for miscarriage of 1.25 (95% CI 
0.63–2.47), comparing users (n = 196) and nonusers (n = 117) 
of inhaled corticosteroids.8 A Canadian study based on the 
Motherisk Program, in which pregnant women voluntarily 
report information relevant to fetal safety after drug use in 
pregnancy, found no increased risk of miscarriage (unad-
justed relative risk 1.01; 95% CI 0.48–2.11) among users of 
oral corticosteroids (n = 187) during pregnancy compared 
with nonusers (n = 188),11 which is in line with our findings. 
In contrast, an Israeli study reported an unadjusted relative 
risk of 1.66 (95% CI 1.12–2.48) for miscarriage among 
oral corticosteroid users (n = 311) compared with nonusers 
(n = 790).10 However, because this study was based on data 
reported to a teratogen information service, the results could 
be susceptible to overestimation due to self-referral bias.40 
In summary, all the evidence taken together indicates that 
an association with miscarriage, if it exists, seems to be 
restricted to inhaled corticosteroids.
Our study was population-based, and we identified cases 
and controls from a larger background population than 
earlier studies.8,10,11 We had access to complete indepen-
dent registration of births, miscarriages, and prescriptions, 
which reduced the risk of selection and information biases. 
Availability of information on gestational age at miscarriage 
allowed us to select controls at the gestational period during 
which they were eligible to become cases and to ascertain 
corticosteroid use in the same preceding gestational period 
for both cases and controls. Finally, animal studies have sug-
gested that corticosteroids reduce fetal growth.41 Therefore, 
corticosteroids could theoretically affect the gestational 
age determined by ultrasound, creating an appearance that 
corticosteroid-affected miscarriages occur earlier in gestation 
than they actually do.
We identified occurrence of miscarriage from hospital-
based diagnoses. The estimated positive predictive value of 
miscarriage diagnoses recorded in the DNRP is 97%.42 Still, 
data may be incomplete because some women with very 
early miscarriage do not seek medical contact or hospital-
ization and are thus not registered.32 An estimated 25% of 
spontaneous abortions reported by women are not registered 
in the DNRP.43
Information on use of corticosteroids was based on pre-
scriptions redeemed before the occurrence of miscarriage. 
However, redeemed prescriptions do not fully reflect the 
timing of drug intake and do not include corticosteroid use 
during hospitalizations. Such errors are unlikely to differ by 
miscarriage status; as a result, estimates of association may 
be diluted.44
We were able to take age, history of diabetes and epilepsy, 
use of NSAIDs, and underlying disease into account in 
our analysis. Although none of these factors affected our 
estimates noticeably, unmeasured confounding cannot be 
ruled out in observational studies. Generally, the data sources 
used for this study, as is common for routine administrative 
registries, do not contain information on smoking, alcohol, 
body mass index, or caffeine intake. Smoking is associated 
with an increased risk of miscarriage.45,46 A Danish 
prevalence study of 832,636 live births from 1996 to 2008, 
with data on maternal smoking recorded in the Medical 
Birth Registry, reported that 18.2% of women who used 
corticosteroids in the first trimester smoked compared with 
19.5% of nonusers.26 Thus, a positive association between 
corticosteroids and miscarriage is unlikely to be explained by 
smoking. Although our study population was larger than that 
in most other studies, the number of informative observations 
in our dataset was low in some subgroups. Therefore, some 
of our estimates are imprecise.
Although physicians always need to be cautious when 
giving medical treatment to pregnant women, not treating 
pregnant women could also put both mother and fetus at risk.47 
For example, untreated asthma has been associated with an 
increased risk of maternal morbidity, eg, exacerbations.48 
The evidence from our study is not sufficient to warrant 
discontinuation of treatment with inhaled corticosteroids 
during pregnancy.
In conclusion, our results suggest a slightly increased 
risk of early miscarriage among women who were current 
users of inhaled corticosteroids but explanations alternative 
to causal ones cannot be ruled out.
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Supplementary Table 1 Codes from the International Classification of Diseases (ICD) and Anatomical Therapeutic Chemical (ATC) 
classification used to identify diagnoses from the Danish National Registry of Patients and to identify dispensing of prescribed drugs 
from the Aarhus University Prescription Database
ICD-8 codes ICD-10 codes ATC codes
Miscarriage 643 O02–O03
induced abortion 640, 641, 642 O04
Asthma 493 J45–J46  
Rheumatoid arthritis 712.19, 712.39, 712.59 M05–M06  
Inflammatory bowel disease 563.00, 563.01, 563.10, 569.02 K51–K50
Diabetes 250 E10–E14
Epilepsy 345 G40  
inhaled corticosteroids R03BA01, R03BA02, R03BA05, R03BA07, 
R03AK06, R03AK07
Oral corticosteroids H02AB04, H02AB06, H02AB07, H02AB09
Nonsteroidal anti-inflammatory drugs M01A
Antidiabetics   A10
Antiepileptics N03A
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